PDCD1 and breast cancer: In patients with BCa, PD-1/PD-L1 blockade has demonstrated significant benefit in patients with unresectable and metastatic BC in the second-line setting, either as monotherapy or in combination with chemotherapy or CTLA-4 checkpoint inhibition (11).